Research findings expected to ease treatment of low neutrophil counts in cancer patients

Mar 10, 2010

For patients like 10-year-old Sabrina Jo Spence, new research led by St. Jude Children's Research Hospital investigators meant fewer injections to combat the drop in white blood cells following her recent chemotherapy.

"Cool," Sabrina told Sheri Spunt, M.D., an associate member of the St. Jude Department of Oncology, after hearing the news and breaking into what Sabrina called her "happy dance." Sabrina is battling rhabdomyosarcoma.

Spunt is Sabrina's doctor and lead author of a study expected to transform how children like Sabrina are treated for neutropenia. Neutropenia is the dangerous drop in that leaves cancer patients at increased risk for infections and can delay . The work appears in the March 10 edition of the .

In a study of 44 young cancer patients, investigators reported that the drugs pegfilgrastim and filgrastim were similarly safe and effective at restoring a safe level of neutrophils following chemotherapy. But pegfilgrastim treatment required a single injection, while filgrastim involved daily injections for a week or longer. The trial was a multicenter, randomized, open-label study to evaluate the safety and efficacy of the two drugs as well as how they are used and metabolized in the body.

"This study will make a big impact on the quality of life for patients and their families," Spunt said.

Both drugs are synthetic growth factors designed to stimulate production of neutrophils. Neutrophils are made in the and protect against bacterial and fungal infections. They are often short-term casualties of chemotherapy. Filgrastim has been widely used to speed neutrophil recovery. Pegfilgrastim was developed as a longer-acting version of filgrastim. It is approved for use in adults.

Although the study focused on patients with sarcomas such as rhabdomyosarcoma and Ewing sarcoma, Spunt said the results will likely change neutropenia treatment for all childhood cancer patients. The study's participants ranged in age from 28 days to 21 years.

"A large percentage of childhood cancer patients get growth factor support during their therapy," Spunt explained. "The injections are painful for patients and difficult for parents, especially the parents of young children who often need two adults to administer the drug daily. The burdens of therapy for them are considerable."

Sabrina, who did not participate in this study, said she became accustomed to the daily shots administered by her grandmother, Alice Spence. But Sabrina always held tight to her mother's hand when the time came. She was happy when the daily injections were replaced by a single shot.

In the study, researchers reported that after the first round of chemotherapy with vincristine, doxorubicin and cyclophosphamide, neutrophil levels started to rise in half the patients five days after treatment with pegfilgrastim, compared with six days for the filgrastim group. By the third round of chemotherapy, which followed additional treatment with ifosfamide and etoposide, half the patients in both groups were improving in seven days.

Both pegfilgrastim and filgrastim are made by Amgen, a California-based pharmaceutical company. Filgrastim is metabolized in the kidneys. Pegfilgrastim includes a polyethylene glycol tail and is broken down by neutrophils. As a result, pegfilgrastim levels drop as the patient's climb.

Explore further: Team identifies source of most cases of invasive bladder cancer

Provided by St. Jude Children's Research Hospital

not rated yet
add to favorites email to friend print save as pdf

Related Stories

Tablet is better all round for cancer patients

Oct 08, 2007

A drug to treat colon cancer is proving much more convenient than traditional chemotherapy, has fewer side effects - and a study of almost 2,000 patients has shown it is giving them a better chance of surviving the disease.

Recommended for you

Cancer stem cells linked to drug resistance

5 hours ago

Most drugs used to treat lung, breast and pancreatic cancers also promote drug-resistance and ultimately spur tumor growth. Researchers at the University of California, San Diego School of Medicine have discovered ...

Unraveling the 'black ribbon' around lung cancer

Apr 17, 2014

It's not uncommon these days to find a colored ribbon representing a disease. A pink ribbon is well known to signify breast cancer. But what color ribbon does one think of with lung cancer?

User comments : 0

More news stories

Less-schooled whites lose longevity, study finds

Barbara Gentry slowly shifts her heavy frame out of a chair and uses a walker to move the dozen feet to a chair not far from the pool table at the Buford Senior Center. Her hair is white and a cough sometimes interrupts her ...

How to keep your fitness goals on track

(HealthDay)—The New Year's resolutions many made to get fit have stalled by now. And one expert thinks that's because many people set their goals too high.

Low tolerance for pain? The reason may be in your genes

Researchers may have identified key genes linked to why some people have a higher tolerance for pain than others, according to a study released today that will be presented at the American Academy of Neurology's 66th Annual ...

Growing app industry has developers racing to keep up

Smartphone application developers say they are challenged by the glut of apps as well as the need to update their software to keep up with evolving phone technology, making creative pricing strategies essential to finding ...

Making graphene in your kitchen

Graphene has been touted as a wonder material—the world's thinnest substance, but super-strong. Now scientists say it is so easy to make you could produce some in your kitchen.